Alpha Interferon as Initial Treatment of Essential Thrombocythemia. Analysis after Two Years of Follow-Up
| Autor: | Ivana Casaroli, Silvia Bolis, Gianmarco Corneo, M Brambilla, F. Rossini, D Fagnani, Isabella Miccolis, D Perego, A Ferrario, Enrico Pogliani |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male 0301 basic medicine Cancer Research medicine.medical_specialty Dose Anemia Alpha (ethology) Alpha interferon Interferon alpha-2 030204 cardiovascular system & hematology Gastroenterology 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Aged Thrombocytosis business.industry Essential thrombocythemia Interferon-alpha General Medicine Middle Aged medicine.disease Recombinant Proteins Clinical trial Treatment Outcome 030104 developmental biology Oncology Toxicity Female business Follow-Up Studies |
| Zdroj: | Tumori Journal. 81:245-248 |
| ISSN: | 2038-2529 0300-8916 |
| DOI: | 10.1177/030089169508100406 |
| Popis: | Aims and background Recombinant alpha-interferon has been shown to be effective in essential thrombocythemia and in thrombocytosis associated with other myeloproliferative disorders. Patients and methods Twenty-five untreated patients were enrolled in our study from May 1989 to April 1992. Recombinant alpha interferon-2b was administered at an initial dose of 2 megaunits (MU)/m2 three times a week at escalating doses to 5 MU/m2 or the maximum tolerated dose. The mean follow-up for patients still in treatment at the time of this report was 35.9 months (range, 24-63). Results Fourteen patients (56%) had achieved a complete remission by a mean time of 152 days; 6 patients (24%) had achieved a good partial remission by a mean of 180 days. In addition to the favorable effect on platelet count, a marked improvement in clinical symptoms was observed. Treatment had to be discontinued in 9 patients (36%), 5 for toxicity (3 neurologic, 1 anemia and 1 severe hypertriglyceridemia) at a median of 155 days from the beginning of therapy (range, 30-400). Four patients refused to continue therapy because of low tolerance (flu-like syndrome) at mean of 160 days from the beginning of therapy (range, 34-301). Conclusions In our study, lower doses were administered compared with previous short-time trials. The present data show that interferon is an effective alternative to cytostatic agents in long-term treatment of patients with essential thrombocythemia, even when used at lower dosages. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|